Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) (NCT04703192)

🧪 Interventions in This Study

• Valemetostat Tosylate (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (60 Sites)

Showing the first 25 of 60 sites.

• City Of Hope National Medical Center — Duarte, California
• Stanford University Medical Center - Cancer Clinical Trials Office - ONCOLOGY — Palo Alto, California
• University of California San Francisco — San Francisco, California
• University Of Colorado Cancer Center — Aurora, Colorado
• Emory University Hospital - Winship Cancer Institute — Atlanta, Georgia
• Northwestern University - Feinberg School of Medicine — Chicago, Illinois
• Dana Farber Cancer Institute — Boston, Massachusetts
• Mayo Clinic - Rochester — Rochester, Minnesota
• Washington University School of Medicine — St Louis, Missouri
• Hackensack University Medical Center - John Theurer Cancer Center — Hackensack, New Jersey
• Memorial Sloan-Kettering Cancer Center at Memorial Hospital — New York, New York
• Weill Cornell Medicine — New York, New York
• Duke Cancer Center — Durham, North Carolina
• University of Pennsylvania Perelman Center for Advanced Medicine — Philadelphia, Pennsylvania
• Epworth Healthcare — Richmond,
• BC Cancer - Vancouver Centre — Vancouver, British Columbia
• Ottawa Hospital Research Institute — Ottawa,
• University Health Network Princess Margaret Hospital — Toronto,
• CHU de Dijon — Dijon,
• CHRU de Lille - Hôpital Claude Huriez - Maladies du Sang — Lille,
• Centre Lyon Berard - Medical Oncology — Lyon,
• APHP - Hopital Saint Louis — Paris,
• Hôpital Necker — Paris,
• Centre Hospitalier Lyon Sud - Hématologie — Pierre-Bénite,
• Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-Oncopole) — Toulouse,

📞 Contact the Study Coordinator

Phone: (800) 826-4673

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

Explore by condition: All Relapsed/Refractory Peripheral T-Cell Lymphoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.